Similar articles for PMID: 30926649

Year	Number of Results
2004	1
2009	2
2010	1
2011	1
2012	3
2013	4
2014	7
2015	11
2016	13
2017	22
2018	19
2019	18
2020	9
2021	8
2022	7
2023	2
2024	0

1

Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸F-FDG PET/CT.

Jadvar H, Velez EM, Desai B, Ji L, Colletti PM, Quinn DI. Jadvar H, et al. J Nucl Med. 2019 Nov;60(11):1524-1530. doi: 10.2967/jnumed.118.223263. Epub 2019 Mar 29. J Nucl Med. 2019. PMID: 30926649 Free PMC article. Clinical Trial.

2

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI. Jadvar H, et al. J Nucl Med. 2013 Aug;54(8):1195-201. doi: 10.2967/jnumed.112.114116. Epub 2013 Jun 19. J Nucl Med. 2013. PMID: 23785174 Free PMC article. Clinical Trial.

3

Increased Prostate Cancer Glucose Metabolism Detected by ¹⁸F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F. Lavallée E, et al. Eur Urol Focus. 2019 Nov;5(6):998-1006. doi: 10.1016/j.euf.2018.03.008. Epub 2018 Mar 30. Eur Urol Focus. 2019. PMID: 29609897

4

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

5

Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study.

Wibmer AG, Morris MJ, Gonen M, Zheng J, Hricak H, Larson S, Scher HI, Vargas HA. Wibmer AG, et al. J Nucl Med. 2021 Aug 1;62(8):1050-1056. doi: 10.2967/jnumed.120.256602. Epub 2021 Jan 8. J Nucl Med. 2021. PMID: 33419944 Free PMC article.

6

GLUT1 expression in high-risk prostate cancer: correlation with ¹⁸F-FDG-PET/CT and clinical outcome.

Meziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallée É, Bergeron M, Brisson H, Champagne A, Neveu B, Lacombe D, Beauregard JM, Buteau FA, Riopel J, Pouliot F. Meziou S, et al. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):441-448. doi: 10.1038/s41391-020-0202-x. Epub 2020 Jan 13. Prostate Cancer Prostatic Dis. 2020. PMID: 31932660

7

High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.

Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin E. Bahri H, et al. J Nucl Med. 2014 Nov;55(11):1786-90. doi: 10.2967/jnumed.114.144386. Epub 2014 Oct 6. J Nucl Med. 2014. PMID: 25286923 Free article.

8

Flare on [¹⁸F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients.

Malaspina S, Ettala O, Tolvanen T, Rajander J, Eskola O, Boström PJ, Kemppainen J. Malaspina S, et al. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):613-621. doi: 10.1007/s00259-022-05970-y. Epub 2022 Sep 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 36161511 Free PMC article.

9

¹⁸F-FDG PET/CT predicts survival after ⁹⁰Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Jreige M, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N. Jreige M, et al. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1215-1222. doi: 10.1007/s00259-017-3653-0. Epub 2017 Feb 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 28233086

10

A Comparison of ¹⁸F-DCFPyL, ¹⁸F-NaF, and ¹⁸F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer.

Fourquet A, Rosenberg A, Mena E, Shih JJ, Turkbey B, Blain M, Bergvall E, Lin F, Adler S, Lim I, Madan RA, Karzai F, Gulley JL, Dahut WL, Wood BJ, Chang R, Levy E, Choyke PL, Lindenberg L. Fourquet A, et al. J Nucl Med. 2022 May;63(5):735-741. doi: 10.2967/jnumed.121.262371. Epub 2021 Sep 2. J Nucl Med. 2022. PMID: 34475237 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

107 results

Results by year